Harmony Biosciences Enters Material Definitive Agreement

Ticker: HRMY · Form: 8-K · Filed: 2024-04-11T00:00:00.000Z

Sentiment: neutral

Topics: material-definitive-agreement, pharmaceuticals

TL;DR

Harmony Bio just signed a big deal, filing shows.

AI Summary

Harmony Biosciences Holdings, Inc. announced on April 6, 2024, the entry into a material definitive agreement. The company, incorporated in Delaware with IRS number 822279923, is involved in the pharmaceutical preparations industry.

Why It Matters

This filing indicates a significant new contract or partnership for Harmony Biosciences, which could impact its future revenue and strategic direction.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood, requiring further analysis.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Harmony Biosciences?

The filing states that Harmony Biosciences Holdings, Inc. entered into a material definitive agreement on April 6, 2024, but the specific details of the agreement are not provided in this excerpt.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on April 6, 2024.

What is Harmony Biosciences Holdings, Inc.'s principal executive office address?

Harmony Biosciences Holdings, Inc.'s principal executive office is located at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462.

What is Harmony Biosciences Holdings, Inc.'s telephone number?

Harmony Biosciences Holdings, Inc.'s telephone number is (484) 539-9800.

What is Harmony Biosciences Holdings, Inc.'s Standard Industrial Classification code?

Harmony Biosciences Holdings, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001558370-24-004945.txt : 20240411 0001558370-24-004945.hdr.sgml : 20240411 20240411083017 ACCESSION NUMBER: 0001558370-24-004945 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240406 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240411 DATE AS OF CHANGE: 20240411 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 24837195 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 8-K 1 hrmy-20240406x8k.htm 8-K 0001802665 false 0001802665 2024-04-06 2024-04-06 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of report (Date of earliest event reported): April 6, 2024 ​ HARMONY BIOSCIENCES HOLDINGS, INC . (Exact name of registrant as specified in its charter) ​ ​ ​ ​ Delaware 001-39450 82-2279923 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) ​ 630 W. Germantown Pike , Suite 215 Plymouth Meeting , PA 19462 (Address of principal executive offices) (Zip Code) ( 484 ) 539-9800 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ ​ ​ ​      Trading      Name of each exchange Title of each class ​ Symbol(s) ​ on which registered Common Stock, $0.00001 par value per share ​ HRMY ​ The Nasdaq Global Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 1.01 Entry into a Material Definitive Agreement. ​ The information under the heading “LCA Amendments” under Item 8.01. Other Events is incorporated in this Item 1.01 by reference. Item 8.01 Other Events. ​ Exclusive Sublicense Agreement On April 11, 2024, Harmony Biosciences Holdings, Inc. announced that its subsidiary Harmony Biosciences, LLC (“Harmony”) entered into a sublicense agreement with Bioprojet Société Civile de Recherche and Bioprojet Pha

View on Read The Filing